Brokerages Expect Affimed NV (NASDAQ:AFMD) Will Announce Quarterly Sales of $6.46 Million
Wall Street brokerages predict that Affimed NV (NASDAQ:AFMD) will announce $6.46 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Affimed’s earnings, with the lowest sales estimate coming in at $6.13 million and the highest estimate coming in at $6.79 million. Affimed reported sales of $180,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 3,488.9%. The firm is expected to report its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Affimed will report full-year sales of $36.57 million for the current fiscal year, with estimates ranging from $13.00 million to $87.20 million. For the next year, analysts forecast that the firm will report sales of $65.34 million, with estimates ranging from $1.00 million to $169.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Affimed.
Affimed (NASDAQ:AFMD) last posted its earnings results on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.19. The firm had revenue of $12.89 million during the quarter, compared to the consensus estimate of $6.77 million. Affimed had a negative net margin of 29.04% and a negative return on equity of 23.61%.
AFMD stock traded up $0.09 during mid-day trading on Tuesday, reaching $2.99. The company had a trading volume of 557,557 shares, compared to its average volume of 1,061,407. The company has a quick ratio of 3.16, a current ratio of 3.17 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $186.55 million, a PE ratio of -7.87 and a beta of 2.84. Affimed has a one year low of $1.40 and a one year high of $7.35. The business has a 50-day moving average price of $3.02.
Institutional investors have recently made changes to their positions in the business. Millennium Management LLC lifted its holdings in shares of Affimed by 7.2% in the 4th quarter. Millennium Management LLC now owns 3,121,914 shares of the biopharmaceutical company’s stock valued at $9,709,000 after acquiring an additional 210,884 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Affimed in the first quarter worth about $253,000. Deutsche Bank AG increased its position in Affimed by 2,243.6% in the fourth quarter. Deutsche Bank AG now owns 49,074 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 46,980 shares during the period. MYDA Advisors LLC increased its position in Affimed by 150.0% in the first quarter. MYDA Advisors LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 30,000 shares during the period. Finally, Barclays PLC increased its position in Affimed by 35.6% in the fourth quarter. Barclays PLC now owns 76,959 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 20,196 shares during the period. Institutional investors own 37.50% of the company’s stock.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.